Type 2 diabetes mellitus
Conditions
Interventions
Under hospitalized for 2 weeks, patients will be orally administered Tenellia 20 mg/day from day 4 to day 10. Then, patients will be taken Canalia 1 tablet/day from day 11 to day 14.
Sponsors
University of Miyazaki , fuculty of medicine, Endocrinology, Metabolism and Diabetes Mellitus, Department of Internal Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The patients aged 20 to 75 years old with type 2 diabetes. HbA1c: 7~10% with no medication or only metformin.
Exclusion criteria
Exclusion criteria: 1. Patient who cannnot regulary visit hospital 2. Patient with advanced diabetic retinopathy 3. Dialysis patient with diabetes 4. Patient who judged inappropriate due to the complications and treatment by attending doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Glycemic control assessed by meal tolerance test and continuous glucose monitoring on each treatment period | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Insulin secretion capacity and pattern 2) Incretin (GLP-1, GIP) secretion capacity and pattern 3) Glucagon secretion capacity and pattern 4) Ghrelin secretion capacity and pattern 5) Des-acyl ghrelin secretion capacity and pattern 6) C peptide secretion capacity and pattern 7) Changes in urine volume, urinary C peptide, urinary protein, and urinary glucose 8) Changes in body weight, body composition, blood pressure, and pulse rate 9) Changes in renal function, liver function, uric acid, serum lipid, keton body, HOMA-R, and HOMA-beta | — |
Countries
Japan
Contacts
Public ContactHiroaki Ueno
University of Miyazaki , fuculty of medicine Endocrinology, Metabolism and Diabetes Mellitus, Department of Internal Medicine
Outcome results
None listed